Labiotech.eu

Inside Labiotech 21 Sep 2017

How we raised our second financing round? (Yes, it was tough)

You might have seen our press release or read about it on other media outlets, such as Tech.eu, EU-Startups, Gruenderszene.de, VC-Magazin, Deutsche-startups.de or Wan-Ifra: we just raised our second financing round. It’s a major milestone for the development of Labiotech.eu as it will allow us to continue investing in amazing content, launch new products and […]

September 21, 2017 - 6 minutesmins - By Philip Hemme

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat tumors. Glythera has teamed up with antibody developer IONTAS to work on a new generation of antibody-drug conjugate (ADC) drugs. As part of the agreement, IONTAS will develop new antibodies against multiple undisclosed targets, on which Glythera will have the option […]

September 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

The FDA has backed Kiadis Pharma’s lead blood cancer product by granting it the Regenerative Medicine Advanced Therapy designation. Kiadis Pharma, based in Amsterdam, develops products to make bone marrow transplants for the treatment of blood cancer and inherited blood disorders safer and more effective. Their lead T cell immunotherapy candidate, ATIR101, reduces the risk of complications, and […]

September 20, 2017 - 2 minutesmins - By Alex Dale

biotech portugal vesalius biocapital fund

News and Trends 20 Sep 2017

Biotech in Portugal gets a Boost with New Investment Fund

Vesalius Biocapital and the Portuguese National Promotional Bank have announced a new joint venture that will invest in late-stage healthcare companies. The Instituição Financeira de Desenvolvimento (IFD), or Portuguese National Promotional Bank, is launching its first joint investment with an international VC, Vesalius Biocapital. Though its size hasn’t been revealed yet, the new fund is a 50/50 venture […]

September 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2017

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

A British-American collaboration’s once-daily triple therapy inhaler has been approved for use by appropriate COPD patients in the US. A new triple therapy inhaler for chronic obstructive pulmonary disease (COPD), Trelegy Ellipta, has been developed by British giant GSK in collaboration with Innoviva in the US. The inhaler is targeted at patients who are struggling with airflow […]

September 20, 2017 - 2 minutesmins - By Alex Dale

What you need to Know about the Legalization of Cannabis for Medical Use

It is mentioned in song texts, studied in scientific papers, listed on political agendas: Cannabis. The global discussion has been raging for decades. Should a drug that is listed as a strong narcotic in many countries be legalized for medicinal or recreational use? In recent years, several countries, including Canada, Italy and the Czech Republic […]

September 20, 2017 - 8 minutesmins - By External Contributor

derek jones babraham bioscience technologies incubator

Interview 20 Sep 2017

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […]

September 20, 2017 - 9 minutesmins - By Evelyn Warner

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

News and Trends 18 Sep 2017

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […]

September 18, 2017 - 2 minutesmins - By Alex Dale

More News! 18 Sep 2017

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […]

September 18, 2017 - 1 minutemin - By Evelyn Warner

News and Trends 18 Sep 2017

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […]

September 18, 2017 - 1 minutemin - By Alex Dale

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […]

September 18, 2017 - 2 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

How we raised our second financing round? (Yes, it was tough)

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer

Dutch Biotech Gets Special Designation for Reduced Risk Blood Cancer Treatment

Biotech in Portugal gets a Boost with New Investment Fund

Once-a-Day Inhaler Approved for Treatment of Deadly Lung Disease in the US

What you need to Know about the Legalization of Cannabis for Medical Use

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!